The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IWWM-12 2024 | Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM
Adam Sperling, MD, PhD, Dana Farber Cancer Institute, Boston, MA, discusses the role of clonal hematopoiesis in the pathogenesis of Waldenström’s macroglobulinemia (WM). He explains that in patients who have asymptomatic WM, the presence of clonal hematopoiesis increases the risk of progression, although the mechanism behind this is not fully understood. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
